FDA to review Bausch + Lomb's intraocular lens

February 27, 2013 by Arezu Sarvestani

Bausch + Lomb lands a panel date with the FDA to review its Trulign Toric vision-correcting implant.

Bausch + Lomb logo

Eye care giant Bausch + Lomb won a date with the FDA for review of its Trulign Toric intraocular lens for improving vision in patient who have undergone cataract surgery.

On April 8, 2012, the FDA's Ophthalmic Devices Panel will review clinical data and cast a vote on the Trulign Toric implant in treatment of patients with vision impairment as a result of aphakia and postoperative refractive astigmatism.

Sign up to get our free newsletters delivered right to your inbox.

Bausch + Lomb is aiming to win indication to treat adult patients "who desire improved uncorrected distance vision and reduction of residual refractive cylinder," according to an FDA report.

The Trulign Toric system would allow post-operative cataract patients to improve near, intermediate and distance vision without glasses, according to the company.

The FDA plans to make more information available prior to the April meeting, according to the notice.

The Trulign Toric would have to compete with similar products already on the market, including the TECNIS Multifocal 1-Piece intraocular lens made by healthcare giant Abbott (NYSE:ABT). That device won expanded FDA approval in March 2010.